期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

节律性化疗在血液肿瘤治疗应用的研究进展 被引量：3

Research progress of metronomic chemotherapy treatment in blood tumor
暂未订购
导出
摘要 近几年发现某些化疗药物在低剂量、长时间接触中可选择性抑制血管内皮细胞的功能,且不受肿瘤细胞耐药状态的影响,与传统的最大耐受量化疗不同,主要是剂量低,间歇期短,能持续应用。本文对节律性化疗在血液病患者中的应用、作用机制、优势及其与其他治疗方法结合等方面的现状和前景进行综述。 In recent years,we found that certain chemotherapy drugs in low dose and prolonged exposure could selectively inhibit vascular endothelial cell function,and not subject to the state of drug- resistant tumor cells,differ from conventional chemotherapy of the maximum tolerated dose mainly in low dose,short intermittent duration,and continuance to apply. In this essay,we reviewed the status quo and prospects of rhythmic chemotherapy in the application,mechanism,advantages and their combination with other treatment methods in patients of hematonosis.
作者 艾工文 孟秀琴
机构地区 上海市第十人民医院血液内科
出处 《现代肿瘤医学》 CAS 2015年第7期1021-1024,共4页 Journal of Modern Oncology
关键词 节律性化疗 持续低剂量化疗 血液病 metronomic chemotherapy continuous low-dose chemotherapy hematonosis
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Schiller JH.Comparison of four chemotherapy regimens for advanced non small-cell lung cancer[J].N Eng J Med,2002,346:92-98.
  • 2Leaf C.Why we are losing the war on cancer (and how to win it)[J].Fortune,2004,149:77-97.
  • 3Hanaban D,Bergers G,Bergsland E.Less is more,regularly:Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice[J].J Clin Invest,2000,105(8):1045-1047.
  • 4Stempak D,Gammon J,Hahon J,et al.A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors[J].J Pediatr Hematol Oncol,2006,28(11):720-728.
  • 5Havrilesky LJ,Alvarez AA,Sayer RA,et al.Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer[J].Gynecol Oncol,2003,88:51-57.
  • 6Sung CC,Chang PY,Chen MF,et al.Successful metronomic low-dose cyclophosphamide therapy in an older patient with advanced mucosa-associated lymphoid tissue lymphoma[J].Ann Hematol,2009,88:1257-1259.
  • 7Buckstein R,Kerbel RS,Shaked Y,et al.High-dose celecoxib and metronomic"low-dose"cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-hodgkin's lymphoma[J].Clin Cancer Res,2006,12(17):5190-5198.
  • 8De Weerdt O,Van de Donk NW,Velh G,et al.Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma[J].Neth J Med,2001,59(2):50-56.
  • 9Trieu Y,Trudel S,Pond GR,et al.Weekly cyclophosphamide and alternate-day prednisone:An effective,convenient,and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation[J].Mayo Clin Proe,2005,80(12):1578-1582.
  • 10Suvannasankha A,Fausel C,Juliar BE,et al.Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide,thalidomide,and prednisone for patients with relapsed or refractory multiple myeloma:A hoosier oncology group trial,HEM01-21[J].Oncologist,2007,12(1):99-106.

同被引文献36

  • 1Patil VM, Noronha V, Joshi A, et al. A prospective randomized phase H study comparing metronomic chemotherapy with chemothera- py (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck [ J ]. Oral Oncol, 2015, 51 ( 3 ) : 279-286.
  • 2Masuda N, Higaki K, Takano T, et al. A phase I1 study of metro- nomic paelitaxel/cyclophosphamide/capecitabine followed by 5-flu- orouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer[ J]. Cancer Chemother Pharmacol, 2014, 74 (2) : 229-238.
  • 3Ferrandina G, Corrado G, Mascilini F, et al. Metronomic oral cyclo- phosphamide (MOC) in the salvage therapy of heavily treated recur- rent ovarian cancer patients : a retrospective, muhicenter study [ J ]. BMC Cancer, 2014, 14: 947.
  • 4Barroso-Sousa R, Da Fonseca LG, Souza KT, et al. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer [ J ]. Med Oncol, 2015, 32(1) : 443.
  • 5Derosa L, Galli L, Orlandi P, et al. Docetaxel plus oral metronomic cyclophosphamide : a phase ]I study with pharmacodynamic and phar- macogenetic analyses in castration-resistant prostate cancer patients [J]. Cancer, 2014, 120(24) : 3923-3931.
  • 6Miger J, Holmqvist A, Sun XF, et al. Low-dose eapecitabine ( Xelo- da) for treatment for gastrointestinal cancer[ J]. Med Oncol, 2014, 31 (3) : 870.
  • 7Alici S, Buyukberber S, Alkis N, et al. Low-dose docetaxel/cispla- tin-leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma[ J]. Asian Pac J Cancer Prey, 2013, 14( 1 ) : 423-427.
  • 8Brandi G, De Rosa F, Agostini V, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase 11 study [ J ]. Oncologist, 2013, 18 (12) : 1256-1257.
  • 9Romiti A, Onesti CE, Roberto M, et al. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer [ J ]. Med Oncol, 2015, 32(3): 54.
  • 10Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophos- phamide in vaccine approaches : a current perspective [ J ]. Cancer Res, 2012, 72 (14) : 3439-3444.

引证文献3

二级引证文献6

现代肿瘤医学
2015年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部